Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection

Aims: To determine the visual outcome following initiation of brimonidine therapy in glaucoma. Methods: 16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pr...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of ophthalmology Vol. 87; no. 12; pp. 1463 - 1465
Main Authors Evans, D W, Hosking, S L, Gherghel, D, Bartlett, J D
Format Journal Article
LanguageEnglish
Published BMA House, Tavistock Square, London, WC1H 9JR BMJ Publishing Group Ltd 01.12.2003
BMJ
BMJ Publishing Group LTD
Copyright 2003 British Journal of Ophthalmology
Subjects
Online AccessGet full text
ISSN0007-1161
1468-2079
DOI10.1136/bjo.87.12.1463

Cover

Abstract Aims: To determine the visual outcome following initiation of brimonidine therapy in glaucoma. Methods: 16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pressure (IOP), blood pressure, and heart rate were evaluated at baseline and after 3 months. Results: IOP reduction was similar for both groups (p<0.05). Brimonidine improved CS; in the right eye at 6 and 12 cpd (p = 0.043, p = 0.017); in the left eye at 3 and 12 cpd (p = 0.044, p = 0.046). Timolol reduced CS at 18 cpd in the right eye (p = 0.041). There was no change in any other measured parameters. Conclusion: Glaucoma patients exhibit improved CS on initiation of brimonidine therapy.
AbstractList Aims: To determine the visual outcome following initiation of brimonidine therapy in glaucoma. Methods: 16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pressure (IOP), blood pressure, and heart rate were evaluated at baseline and after 3 months. Results: IOP reduction was similar for both groups (p<0.05). Brimonidine improved CS; in the right eye at 6 and 12 cpd (p = 0.043, p = 0.017); in the left eye at 3 and 12 cpd (p = 0.044, p = 0.046). Timolol reduced CS at 18 cpd in the right eye (p = 0.041). There was no change in any other measured parameters. Conclusion: Glaucoma patients exhibit improved CS on initiation of brimonidine therapy.
To determine the visual outcome following initiation of brimonidine therapy in glaucoma.AIMSTo determine the visual outcome following initiation of brimonidine therapy in glaucoma.16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pressure (IOP), blood pressure, and heart rate were evaluated at baseline and after 3 months.METHODS16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pressure (IOP), blood pressure, and heart rate were evaluated at baseline and after 3 months.IOP reduction was similar for both groups (p<0.05). Brimonidine improved CS; in the right eye at 6 and 12 cpd (p=0.043, p=0.017); in the left eye at 3 and 12 cpd (p=0.044, p=0.046). Timolol reduced CS at 18 cpd in the right eye (p=0.041). There was no change in any other measured parameters.RESULTSIOP reduction was similar for both groups (p<0.05). Brimonidine improved CS; in the right eye at 6 and 12 cpd (p=0.043, p=0.017); in the left eye at 3 and 12 cpd (p=0.044, p=0.046). Timolol reduced CS at 18 cpd in the right eye (p=0.041). There was no change in any other measured parameters.Glaucoma patients exhibit improved CS on initiation of brimonidine therapy.CONCLUSIONGlaucoma patients exhibit improved CS on initiation of brimonidine therapy.
Aims: To determine the visual outcome following initiation of brimonidine therapy in glaucoma. Methods: 16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pressure (IOP), blood pressure, and heart rate were evaluated at baseline and after 3 months. Results: IOP reduction was similar for both groups (p<0.05). Brimonidine improved CS; in the right eye at 6 and 12 cpd (p = 0.043, p = 0.017); in the left eye at 3 and 12 cpd (p = 0.044, p = 0.046). Timolol reduced CS at 18 cpd in the right eye (p = 0.041). There was no change in any other measured parameters. Conclusion: Glaucoma patients exhibit improved CS on initiation of brimonidine therapy.
To determine the visual outcome following initiation of brimonidine therapy in glaucoma. 16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pressure (IOP), blood pressure, and heart rate were evaluated at baseline and after 3 months. IOP reduction was similar for both groups (p<0.05). Brimonidine improved CS; in the right eye at 6 and 12 cpd (p=0.043, p=0.017); in the left eye at 3 and 12 cpd (p=0.044, p=0.046). Timolol reduced CS at 18 cpd in the right eye (p=0.041). There was no change in any other measured parameters. Glaucoma patients exhibit improved CS on initiation of brimonidine therapy.
Audience Professional
Academic
Author Hosking, S L
Bartlett, J D
Evans, D W
Gherghel, D
AuthorAffiliation 1 School of Optometry, University of Alabama at Birmingham, Birmingham, AL, USA
2 Neuroscience Research Institute, Aston University, Aston Triangle, Birmingham B4 7ET, UK
3 School of Optometry, University of Alabama at Birmingham, and Department of Pharmacology and Toxicology, School of Medicine, University of Alabama, Birmingham, AL, USA
AuthorAffiliation_xml – name: 3 School of Optometry, University of Alabama at Birmingham, and Department of Pharmacology and Toxicology, School of Medicine, University of Alabama, Birmingham, AL, USA
– name: 1 School of Optometry, University of Alabama at Birmingham, Birmingham, AL, USA
– name: 2 Neuroscience Research Institute, Aston University, Aston Triangle, Birmingham B4 7ET, UK
Author_xml – sequence: 1
  givenname: D W
  surname: Evans
  fullname: Evans, D W
  organization: School of Optometry, University of Alabama at Birmingham, and Department of Pharmacology and Toxicology, School of Medicine, University of Alabama, Birmingham, AL, USA
– sequence: 2
  givenname: S L
  surname: Hosking
  fullname: Hosking, S L
  organization: School of Optometry, University of Alabama at Birmingham, and Department of Pharmacology and Toxicology, School of Medicine, University of Alabama, Birmingham, AL, USA
– sequence: 3
  givenname: D
  surname: Gherghel
  fullname: Gherghel, D
  organization: School of Optometry, University of Alabama at Birmingham, and Department of Pharmacology and Toxicology, School of Medicine, University of Alabama, Birmingham, AL, USA
– sequence: 4
  givenname: J D
  surname: Bartlett
  fullname: Bartlett, J D
  organization: School of Optometry, University of Alabama at Birmingham, and Department of Pharmacology and Toxicology, School of Medicine, University of Alabama, Birmingham, AL, USA
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15811123$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/14660453$$D View this record in MEDLINE/PubMed
BookMark eNqFksuLFDEQhxtZcR969SgBUfDQYx7TSdqDsAzurrDoxccxpNOV2YzdyZhkBve_N82MsyorkkORyle_euW0OvLBQ1U9JXhGCOOvu1WYSTEjdEbmnD2oToqRNcWiPapOMMaiJoST4-o0pVW5Uk7Eo-q4QBzPG3ZSxUXwOeqUUQKfXHZbl2-RG9cxbCEhbTNE1EU3Bu965wHlG4h6XRCP1sWt4y0Ka_BI--UAaDnojQmjfoM0MjoBsiEiD5sYimAGk13wj6uHVg8JnuztWfX54t2nxVV9_fHy_eL8uu6aluW6J0B5b0wP2jDbWNtg2pumbxkxgko7xxIaEMxKyjuqeddqDY3ktO9aa4VkZ9Xbne56043QG5gaHdS-ahW0U3--eHejlmGrSEtxI3gReLkXiOH7BlJWo0sGhkF7CJukBJkzLltSwOd_gauwib40p4gQssVMyEmu3lFLPYBy3oaS1SzBl4EOZavWFfc5IaQVhDNc-Nk9fDk9jM7cG_Ds94YPnf7adgFe7AGdjB5s1N64dMc1sojRiZvvOBNDShGsMi7raXelAjcogtX0-VT5fEoKReiUgt0VfAg7KP8rYD8RlzL8ONA6flNcMNGoD18WSlwuvnIsrtRF4V_t-G5c_U_7J6dQ-mc
CODEN BJOPAL
CitedBy_id crossref_primary_10_1016_j_exer_2006_10_002
crossref_primary_10_1016_j_ophtha_2014_04_014
crossref_primary_10_1016_j_ajo_2005_03_058
crossref_primary_10_1038_eye_2008_226
crossref_primary_10_4103_ijo_IJO_1158_21
crossref_primary_10_4103_meajo_MEAJO_259_17
crossref_primary_10_56951_medicinus_v36i2_119
crossref_primary_10_1038_s41433_022_02305_x
crossref_primary_10_4236_ojoph_2012_23013
crossref_primary_10_1016_j_preteyeres_2024_101261
crossref_primary_10_1093_ageing_afp259
crossref_primary_10_1111_j_1442_9071_2008_01720_x
crossref_primary_10_1111_j_1442_9071_2009_02108_x
crossref_primary_10_3233_JAD_220016
crossref_primary_10_1016_j_preteyeres_2018_04_001
crossref_primary_10_1111_ceo_13818
crossref_primary_10_1089_jop_2007_0106
crossref_primary_10_21516_2072_0076_2023_16_4_147_151
crossref_primary_10_1089_jop_2007_0127
crossref_primary_10_1016_j_ophtha_2013_12_011
crossref_primary_10_1016_j_ajo_2020_04_032
crossref_primary_10_1089_jop_2011_0014
crossref_primary_10_1111_j_1755_3768_2011_02130_x
crossref_primary_10_1155_2017_4586763
crossref_primary_10_1089_jop_2007_0022
crossref_primary_10_1007_s00417_005_1160_7
crossref_primary_10_1089_jop_2005_21_475
crossref_primary_10_1111_ceo_14120
crossref_primary_10_1002_14651858_CD006539_pub4
crossref_primary_10_1016_j_survophthal_2020_12_004
crossref_primary_10_17116_oftalma2019135031113
crossref_primary_10_2147_OPTH_S369626
crossref_primary_10_3390_cells9122594
crossref_primary_10_3390_ph17101261
crossref_primary_10_1586_eop_10_69
crossref_primary_10_3390_futurepharmacol4020022
crossref_primary_10_1016_j_ajo_2009_03_029
crossref_primary_10_1016_j_coph_2012_08_005
crossref_primary_10_1097_MD_0000000000020380
crossref_primary_10_1111_ceo_13336
crossref_primary_10_1111_j_1442_9071_2011_02563_x
crossref_primary_10_1155_2017_4320408
crossref_primary_10_1038_cddis_2016_397
crossref_primary_10_1007_s10792_022_02603_z
crossref_primary_10_3390_jpm12111884
crossref_primary_10_1016_j_exer_2011_04_002
crossref_primary_10_1167_iovs_19_27113
crossref_primary_10_1016_j_preteyeres_2020_100881
ContentType Journal Article
Copyright Copyright 2003 British Journal of Ophthalmology
2004 INIST-CNRS
COPYRIGHT 2003 BMJ Publishing Group Ltd.
Copyright: 2003 Copyright 2003 British Journal of Ophthalmology
Copyright © Copyright 2003 British Journal of Ophthalmology 2003
Copyright_xml – notice: Copyright 2003 British Journal of Ophthalmology
– notice: 2004 INIST-CNRS
– notice: COPYRIGHT 2003 BMJ Publishing Group Ltd.
– notice: Copyright: 2003 Copyright 2003 British Journal of Ophthalmology
– notice: Copyright © Copyright 2003 British Journal of Ophthalmology 2003
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
BTHHO
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1136/bjo.87.12.1463
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
BMJ Journals
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
BMJ Journals
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

MEDLINE

ProQuest One Academic Middle East (New)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-2079
EndPage 1465
ExternalDocumentID PMC1920576
4012344701
A111971630
14660453
15811123
10_1136_bjo_87_12_1463
ark_67375_NVC_7GCW607H_F
bjophthalmol
Genre Comparative Study
Clinical Trial
Randomized Controlled Trial
Journal Article
GroupedDBID ---
-~X
.55
.GJ
.VT
0R~
18M
23N
2WC
354
39C
3O-
4.4
40O
53G
5GY
5RE
5VS
6J9
7X7
7~S
88E
8FI
8FJ
8R4
8R5
AAHLL
AAKAS
AAOJX
AAWJN
ABAAH
ABJNI
ABKDF
ABMQD
ABTFR
ABUWG
ABVAJ
ACCCW
ACGFO
ACGFS
ACGTL
ACHTP
ACMFJ
ACNCT
ACOAB
ACOFX
ACQSR
ACTZY
ADBBV
ADCEG
ADZCM
AENEX
AFKRA
AFWFF
AGQPQ
AHMBA
AHNKE
AHQMW
AJYBZ
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AZFZN
BAWUL
BENPR
BLJBA
BOMFT
BPHCQ
BTFSW
BTHHO
BVXVI
C1A
C45
CAG
CCPQU
COF
CS3
CXRWF
DIK
DU5
E3Z
EBS
EJD
F5P
FYUFA
H13
HAJ
HMCUK
HYE
HZ~
IAO
IEA
IHR
IOF
ITC
J5H
KQ8
L7B
M1P
N9A
NTWIH
NXWIF
O9-
OK1
OVD
P2P
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
R53
RHI
RMJ
RPM
RV8
TEORI
TR2
UAW
UKHRP
UYXKK
V24
VM9
W8F
WH7
WOQ
X7M
XOL
YFH
YQY
ZGI
3V.
BSCLL
RHF
AAFWJ
AAYXX
ACQHZ
AERUA
CITATION
PHGZM
IQODW
PJZUB
PPXIY
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-b593t-d1e26dccdeac3f5ff502dc5d931c728f408e5e73f826b2a6b9aae5862db9ff783
IEDL.DBID 7X7
ISSN 0007-1161
IngestDate Thu Aug 21 14:11:27 EDT 2025
Thu Sep 04 16:27:09 EDT 2025
Fri Jul 25 05:15:14 EDT 2025
Fri Jun 13 00:49:10 EDT 2025
Tue Jun 10 21:26:32 EDT 2025
Thu Jan 02 23:03:59 EST 2025
Mon Jul 21 09:13:46 EDT 2025
Thu Apr 24 23:01:14 EDT 2025
Tue Jul 01 00:53:24 EDT 2025
Wed Oct 30 09:22:17 EDT 2024
Thu Apr 24 23:02:35 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords Antiglaucomatous agent
Human
α2-Adrenergic receptor
Quinoxaline derivatives
Therapy
Open angle glaucoma
Brimonidine
Contrast
Chemotherapy
Sensitivity
Treatment
Primary
α-Adrenergic receptor agonist
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b593t-d1e26dccdeac3f5ff502dc5d931c728f408e5e73f826b2a6b9aae5862db9ff783
Notes ark:/67375/NVC-7GCW607H-F
PMID:14660453
Correspondence to: Sarah L Hosking Neuroscience Research Institute, Aston University, Aston Triangle, Birmingham B4 7ET, UK; s.l.hosking@aston.ac.uk
href:bjophthalmol-87-1463.pdf
istex:4E9AA1558A582EB725B49362A05900CB4896D6B6
local:0871463
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
Correspondence to: …Sarah L Hosking …Neuroscience Research Institute, Aston University, Aston Triangle, Birmingham B4 7ET, UK; s.l.hosking@aston.ac.uk
OpenAccessLink https://bjo.bmj.com/content/bjophthalmol/87/12/1463.full.pdf
PMID 14660453
PQID 1778903786
PQPubID 2041039
PageCount 3
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_1920576
proquest_miscellaneous_71436891
proquest_journals_1778903786
gale_infotracgeneralonefile_A111971630
gale_infotracacademiconefile_A111971630
pubmed_primary_14660453
pascalfrancis_primary_15811123
crossref_citationtrail_10_1136_bjo_87_12_1463
crossref_primary_10_1136_bjo_87_12_1463
istex_primary_ark_67375_NVC_7GCW607H_F
bmj_primary_10_1136_bjo_87_12_1463
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2003-12-01
PublicationDateYYYYMMDD 2003-12-01
PublicationDate_xml – month: 12
  year: 2003
  text: 2003-12-01
  day: 01
PublicationDecade 2000
PublicationPlace BMA House, Tavistock Square, London, WC1H 9JR
PublicationPlace_xml – name: BMA House, Tavistock Square, London, WC1H 9JR
– name: London
– name: England
PublicationTitle British journal of ophthalmology
PublicationTitleAlternate Br J Ophthalmol
PublicationYear 2003
Publisher BMJ Publishing Group Ltd
BMJ
BMJ Publishing Group LTD
Copyright 2003 British Journal of Ophthalmology
Publisher_xml – name: BMJ Publishing Group Ltd
– name: BMJ
– name: BMJ Publishing Group LTD
– name: Copyright 2003 British Journal of Ophthalmology
SSID ssj0002617
Score 2.0019495
Snippet Aims: To determine the visual outcome following initiation of brimonidine therapy in glaucoma. Methods: 16 newly diagnosed previously untreated glaucoma...
To determine the visual outcome following initiation of brimonidine therapy in glaucoma. 16 newly diagnosed previously untreated glaucoma patients were...
To determine the visual outcome following initiation of brimonidine therapy in glaucoma.AIMSTo determine the visual outcome following initiation of brimonidine...
Aims: To determine the visual outcome following initiation of brimonidine therapy in glaucoma. Methods: 16 newly diagnosed previously untreated glaucoma...
SourceID pubmedcentral
proquest
gale
pubmed
pascalfrancis
crossref
istex
bmj
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1463
SubjectTerms Adrenergic alpha-Agonists - therapeutic use
Adrenergic beta-Antagonists - therapeutic use
Analysis of Variance
Biological and medical sciences
brimonidine
Brimonidine Tartrate
Care and treatment
Clinical Science - Scientific Reports
Contrast Sensitivity
Defects
Disease
Drug dosages
Eye
Glaucoma
Glaucoma, Open-Angle - drug therapy
Glaucoma, Open-Angle - physiopathology
Humans
Intraocular Pressure - drug effects
Investigations
Medical sciences
Middle Aged
neuroprotection
Ophthalmology
Pharmacology. Drug treatments
primary open angle glaucoma
Quinoxalines - therapeutic use
Receptors, Adrenergic, alpha-2 - drug effects
Retina
Retinopathies
timolol
Timolol - therapeutic use
Title Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection
URI http://bjo.bmj.com/content/87/12/1463.full
https://api.istex.fr/ark:/67375/NVC-7GCW607H-F/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/14660453
https://www.proquest.com/docview/1778903786
https://www.proquest.com/docview/71436891
https://pubmed.ncbi.nlm.nih.gov/PMC1920576
Volume 87
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1468-2079
  dateEnd: 20051231
  omitProxy: true
  ssIdentifier: ssj0002617
  issn: 0007-1161
  databaseCode: KQ8
  dateStart: 19170101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1468-2079
  dateEnd: 20071231
  omitProxy: true
  ssIdentifier: ssj0002617
  issn: 0007-1161
  databaseCode: DIK
  dateStart: 19170101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1468-2079
  dateEnd: 20071231
  omitProxy: true
  ssIdentifier: ssj0002617
  issn: 0007-1161
  databaseCode: RPM
  dateStart: 19170101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1468-2079
  dateEnd: 20250330
  omitProxy: true
  ssIdentifier: ssj0002617
  issn: 0007-1161
  databaseCode: 7X7
  dateStart: 19220101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1468-2079
  dateEnd: 20250330
  omitProxy: true
  ssIdentifier: ssj0002617
  issn: 0007-1161
  databaseCode: BENPR
  dateStart: 19220101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9MwELdglRAviG8Co1gIsaewJI4_ygsa1UqFtAohBn2zHNsZHSMdTSvx53OXuClBA55zck72-fzz3fl3hLwoVc5zn2OGtfBxnhkWG2ZGcZExbg3g68zi4-STmZie5u_nfB4CbnUoq9z6xMZRu6XFGPlhKvHJJpNKvLn8EWPXKMyuhhYa18kgBaiCVi3n3YWrYRtv4a-MU4A2gbQxZeKwOF--UhIjgeAqkDKw-H7eO5qCgx7gZP_EiklTw6SVbbeLq-Don1WVvx1Tk9vkVsCX9Kg1iDvkmq_ukhsnIYN-j6yQjmpl6jWtsXS97R1BF01owde0aRlOixWsYLWAY83T9oEWiFT0smWmoNhxi5rq7MJTAN8bmD_zmhpq4UCkgIFpw5EZCCBg2e-T08nxp_E0Dn0X4oKP2Dp2qc-Es9aBU2YlL0ueZM5yN2KplZkq80R57iUr4WpSZEYUI2M8h6uRKzACrNgDslctK_-IUPhYclVy7pzKywSFjE-Fy5H43SU2Is9h4nXQXzc3EiY0rI5WUqcZ3kxYROLtumgbmMuxgcbFX-UPOvn_jXyAy6xxM8OI1oQ3CaA80mLpoxSzrABZk4i87EmetaTgVwo2JtP92ay-YfGc5Hr2eazlu_EXkcipnkRk2LOpnapcwWgZKLe_NTIdHEutd9sgIs-6z-ASMM9jKr_c1Bpb2gs1SiPysLXI3dC5EIDhYWjZs9VOAMnG-1-qxdeGdBy2F0B78fjfSj0hN9tqR6z32Sd769XGPwXUti6GzdYcksHb49mHj78AG2xDrw
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGJgEviG8CY7MQsKdsSfyVIiE0FUrH1j5t0Dfj2M7WbaSjaQX8U_yN3CVpS9GApz37dLV6l_Pv7LvfEfI8T7ngnuMLa-ZDnhgWGmZaYZYwYQ3g68Ric3KvL7tH_MNADFbIz1kvDJZVzmJiFajdyOId-U6ssGWTqVS-ufga4tQofF2djdCo3WLf__gGKVv5eu8t2PdFknTeHba7YTNVIMxEi01CF_tEOmsdhByWizwXUeKscC0WW5WkOY9SL7xiOQDvLDEyaxnjBQB_l-H9ZspA7zWyxlnEkatfDeYJXsVuXsNtFcYApRqSyJjJnex0tJ0qvHmE0IQUhdmX06WjsDkQ1tC437FC05RgpLyernEZ_P2zivO3Y7Fzm9xq8CzdrR3wDlnxxV1yvde82N8jY6S_GptyQkssla9nVdBhdZXhS1qNKKfZGDymGMIx6mndEAYiBb2omTAoTviipjg-9xTA_hTsZV5RQy0cwBQwN604ORvCCXCz--ToSizygKwWo8I_IhQWc5HmQjiX8jxCIeNj6TgSzbvIBuQZ_PG62b-uMiAmNVhHp0rHCWZCLCDhzC7aNkzpOLDj_K_yW3P5_2neQjNrDB6g0ZqmBwI2jzRcejfGV12AyFFAXi5JHtck5JcKVi4z_2UzPsNiPSV0_2Nbq_ftTzJSXd0JyMaSTy22KlLQlsDm1mdOpptAVurFZxeQzfkyhCB8VzKFH01LrWIcY9CKA_Kw9siFai4l5AygWi356lwAyc2XV4rhSUVyDpkHpBLy8b83tUludA97B_pgr7__hNysKy2x1midrE7GU_8UEOMk26g-U0o-X3Vc-AXdvoEl
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGJk28IL4JjM1CwJ5CEzuOUySEpo7SMVbxwKBvnuPYo_tIR9MK-Nf467hL3JaiAU979ul66l3uw777HSFPXZaIxCb4wprbMGGah5rrdpgzLoyG_JoZHE4-6Ke9w-TdQAxWyM_ZLAy2Vc58Yu2oi5HBO_JWLHFkk8ssbTnfFvFht_v64muIG6TwpXW2TqMxkX374xuUb9WrvV3Q9TPGum8-dnqh3zAQ5qLNJ2ERW5YWxhTgfrgTzomIFUYUbR4byTKXRJkVVnIHSXjOdJq3tbYCioAix7vOjAPfa2RN8oRjO5kczIu9Gum8Sb1lGENa5QEjY5628pPRi0ziLSS4KYQrzM9PlsKiDw5rqOjv2K2pK1CYazZtXJYK_9nR-VuI7N4kN3xuS3caY7xFVmx5m6wf-Nf7O2SMUFhjXU1ohW3zzd4KOqyvNWxF63XlNB-D9ZRDCKmWNsNhQFLSiwYVg-K2L6rL4zNLIfGfgu70S6qpgWBMIf-mNT6nB58Ak7tLDq9EI_fIajkq7QNC4dCJzAlRFFniIiTSNk6LBEHni8gE5An88crLr-pqiKcKtKMyqWKGVREPSDjTizIeNR2Xd5z9lX57Tv8_ztuoZoWOBDga7echQHiE5FI7Mb7wQrocBeT5EuVxA0h-KWFtMvNf1uNTbNyTQvU_dZR82_mcRrKnugHZXLKphagiA24MhNuYGZnyTq1Si08wIFvzY3BH-MakSzuaVkrGuNKgHQfkfmORC9ZJmkL9AKzlkq3OCRDofPmkHH6pAc-hCoGyIn34b6G2yDp4BPV-r7__iFxvmi6x7WiDrE7GU_sYksdJvll_pZQcXbVb-AXXioVg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Contrast+sensitivity+improves+after+brimonidine+therapy+in+primary+open+angle+glaucoma%3A+a+case+for+neuroprotection&rft.jtitle=British+journal+of+ophthalmology&rft.au=Evans%2C+D+W&rft.au=Hosking%2C+S+L&rft.au=Gherghel%2C+D&rft.au=Bartlett%2C+J+D&rft.date=2003-12-01&rft.issn=0007-1161&rft.volume=87&rft.issue=12&rft.spage=1463&rft_id=info:doi/10.1136%2Fbjo.87.12.1463&rft_id=info%3Apmid%2F14660453&rft.externalDocID=14660453
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1161&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1161&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1161&client=summon